{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Amyotrophic lateral sclerosis", "aging", "neurodegenerative diseases", "pathogenesis", "statins"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38903602", "DateRevised": {"Year": "2024", "Month": "06", "Day": "22"}, "Article": {"Language": ["eng"], "ELocationID": ["1422912", "10.3389/fnins.2024.1422912"], "ArticleDate": [{"Year": "2024", "Month": "06", "Day": "05"}], "Journal": {"ISSN": "1662-4548", "JournalIssue": {"Volume": "18", "PubDate": {"Year": "2024"}}, "Title": "Frontiers in neuroscience", "ISOAbbreviation": "Front Neurosci"}, "ArticleTitle": "The role of statins in amyotrophic lateral sclerosis: protective or not?", "Pagination": {"StartPage": "1422912", "MedlinePgn": "1422912"}, "Abstract": {"AbstractText": ["Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of motor neurons characterized by muscle weakness, muscle twitching, and muscle wasting. ALS is regarded as the third-most frequent neurodegenerative disease, subsequent to Alzheimer's disease (AD) and Parkinson's disease (PD). The World Health Organization (WHO) in 2007 declared that prolonged use of statins may induce development of ALS-like syndrome and may increase ALS risk. Subsequently, different studies have implicated statins in the pathogenesis of ALS. In contrast, results from preclinical and clinical studies highlighted the protective role of statins against ALS neuropathology. Recently, meta-analyses and systematic reviews illustrated no association between long-term use of statins and ALS risk. These findings highlighted controversial points regarding the effects of statins on ALS pathogenesis and risk. The neuroprotective effects of statins against the development and progression of ALS may be mediated by regulating dyslipidemia and inflammatory changes. However, the mechanism for induction of ALS neuropathology by statins may be related to the dysregulation of liver X receptor signaling (LXR) signaling in the motor neurons and reduction of cholesterol, which has a neuroprotective effect against ALS neuropathology. Nevertheless, the exact role of statins on the pathogenesis of ALS was not fully elucidated. Therefore, this narrative review aims to discuss the role of statins in ALS neuropathology."], "CopyrightInformation": "Copyright \u00a9 2024 Al-kuraishy, Jabir, Sulaiman, Mohammed, Al-Gareeb, Albuhadily, Jawad, Swelum and Abomughaid."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq."}], "LastName": "Al-Kuraishy", "ForeName": "Hayder M", "Initials": "HM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Applied Sciences, University of Technology, Baghdad, Iraq."}], "LastName": "Jabir", "ForeName": "Majid S", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Applied Sciences, University of Technology, Baghdad, Iraq."}], "LastName": "Sulaiman", "ForeName": "Ghassan M", "Initials": "GM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt."}], "LastName": "Mohammed", "ForeName": "Hamdoon A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacology and Medicine, College of Medicine, Jabir Ibn Hayyan Medical University, Kufa, Iraq."}], "LastName": "Al-Gareeb", "ForeName": "Ali I", "Initials": "AI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq."}], "LastName": "Albuhadily", "ForeName": "Ali K", "Initials": "AK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, Al-Mustaqbal University College, Hillah, Iraq."}], "LastName": "Jawad", "ForeName": "Sabrean F", "Initials": "SF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Animal Production, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Swelum", "ForeName": "Ayman A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia."}], "LastName": "Abomughaid", "ForeName": "Mosleh M", "Initials": "MM"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Neurosci", "NlmUniqueID": "101478481", "ISSNLinking": "1662-453X"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Ali N. H., Al-Kuraishy H. M., Al-Gareeb A. I., Alnaaim S. A., Alexiou A., Papadakis M., et al. . (2024). Neprilysin inhibitors and risk of Alzheimer's disease: a future perspective. J. Cell. Mol. Med. 28:e17993. 10.1111/jcmm.17993", "ArticleIdList": ["10.1111/jcmm.17993", "PMC10826440", "37847125"]}, {"Citation": "Al-Kuraishy H. M., Abdulhadi M. H., Hussien N. R., Al-Niemi M. S., Rasheed H. A., Al-Gareeb A. I. (2020a). Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review. Brain Circ. 6, 70\u201380. 10.4103/bc.bc_42_19", "ArticleIdList": ["10.4103/bc.bc_42_19", "PMC7511915", "33033776"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I. (2016). Effects of rosuvastatin alone or in combination with omega-3 fatty acid on adiponectin levels and cardiometabolic profile. J. basic Clin. Pharm. 8:8. 10.4103/0976-0105.195080", "ArticleIdList": ["10.4103/0976-0105.195080", "PMC5201066", "28104968"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I. (2017). Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: role of statins. J. Lab. Physicians 9, 163\u2013169. 10.4103/0974-2727.208263", "ArticleIdList": ["10.4103/0974-2727.208263", "PMC5496293", "28706385"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I., Al-Buhadilly A. K. (2018a). Rosuvastatin improves vaspin serum levels in obese patients with acute coronary syndrome. Diseases 6:9. 10.3390/diseases6010009", "ArticleIdList": ["10.3390/diseases6010009", "PMC5871955", "29337850"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I., Alexiou A., Papadakis M., Alsayegh A. A., Almohmadi N. H., et al. . (2023a). Pros and cons for statins use and risk of Parkinson's disease: an updated perspective. Pharmacol. Res. Perspect. 11:e01063. 10.1002/prp2.1063", "ArticleIdList": ["10.1002/prp2.1063", "PMC9944858", "36811160"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I., Alsayegh A. A., Hakami Z. H., Khamjan N. A., Saad H. M., et al. . (2023b). A potential link between visceral obesity and risk of Alzheimer's disease. Neurochem. Res. 48, 745\u2013766. 10.1007/s11064-022-03817-4", "ArticleIdList": ["10.1007/s11064-022-03817-4", "36409447"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I., Hussien N. R., Al-Naimi M. S., Rasheed H. A. (2019). Statins an oft-prescribed drug is implicated in peripheral neuropathy: the time to know more. J. Pak. Med. Assoc. 69, S108\u2013S112.", "ArticleIdList": ["31603889"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I., Naji M. T. (2020b). Brain natriuretic peptide in patients with acute ischemic stroke: role of statins. Biomed. Biotechnol. Res. J. 4, 239\u2013245. 10.4103/bbrj.bbrj_44_20", "ArticleIdList": ["10.4103/bbrj.bbrj_44_20"]}, {"Citation": "Al-Kuraishy H. M., Al-Gareeb A. I., Waheed H. J. (2018b). Lipoprotein-associated phospholipase A2 is linked with poor cardio-metabolic profile in patients with ischemic stroke: a study of effects of statins. J. Neurosci. Rural Pract. 9, 496\u2013503. 10.4103/jnrp.jnrp_97_18", "ArticleIdList": ["10.4103/jnrp.jnrp_97_18", "PMC6126307", "30271040"]}, {"Citation": "Al-Kuraishy H. M., Hussian N. R., Al-Naimi M. S., Al-Gareeb A. I. (2020c). Statins role in vitiligo: a mini-review. Turk. J. Dermatol. 14, 1\u20137. 10.4103/TJD.TJD_38_19", "ArticleIdList": ["10.4103/TJD.TJD_38_19", "0"]}, {"Citation": "Al-Kuraishy H. M., Jabir M. S., Al-Gareeb A. I., Albuhadily A. K. (2023c). The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways. Ageing Res. Rev. 91:102075. 10.1016/j.arr.2023.102075", "ArticleIdList": ["10.1016/j.arr.2023.102075", "37714384"]}, {"Citation": "Alromi D., Madani S., Seifalian A. (2021). Emerging application of magnetic nanoparticles for diagnosis and treatment of cancer. Polymers 13:4146. 10.3390/polym13234146", "ArticleIdList": ["10.3390/polym13234146", "PMC8659429", "34883649"]}, {"Citation": "Alrouji M., Al-Kuraishy H. M., Al-Gareeb A. I., Ashour N. A., Jabir M. S., Negm W. A., et al. . (2024). Metformin role in Parkinson's disease: a double-sword effect. Mol. Cell. Biochem. 479, 975\u2013991. 10.1007/s11010-023-04771-7", "ArticleIdList": ["10.1007/s11010-023-04771-7", "37266747"]}, {"Citation": "Al-Rubiay H. F., Al-Kuraishy H. M., Al-Gareeb A. I. (2021). Intercellular adhesive molecule 1 (ICAM-1) and acute ischaemic stroke: role of statins. J. Pak. Med. Assoc. 71, S11\u2013S16.", "ArticleIdList": ["35130210"]}, {"Citation": "Alsubaie N., Al-Kuraishy H. M., Al-Gareeb A. I., Alharbi B., De Waard M., Sabatier J.-M., et al. . (2022). Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci. 12:1290. 10.3390/brainsci12101290", "ArticleIdList": ["10.3390/brainsci12101290", "PMC9599431", "36291224"]}, {"Citation": "Andrews J. A., Jackson C. E., Heiman-Patterson T. D., Bettica P., Brooks B. R., Pioro E. P. (2020). Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 21, 509\u2013518. 10.1080/21678421.2020.1771734", "ArticleIdList": ["10.1080/21678421.2020.1771734", "32573277"]}, {"Citation": "Bagheri H., Ghasemi F., Barreto G. E., Sathyapalan T., Jamialahmadi T., Sahebkar A. (2020). The effects of statins on microglial cells to protect against neurodegenerative disorders: a mechanistic review. Biofactors 46, 309\u2013325. 10.1002/biof.1597", "ArticleIdList": ["10.1002/biof.1597", "31846136"]}, {"Citation": "Bandres-Ciga S., Noyce A. J., Hemani G., Nicolas A., Calvo A., Mora G., et al. . (2019). Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann. Neurol. 85, 470\u2013481. 10.1002/ana.25431", "ArticleIdList": ["10.1002/ana.25431", "PMC6450729", "30723964"]}, {"Citation": "Bede P., Murad A., Hardiman O. (2021). Pathological neural networks and artificial neural networks in ALS: diagnostic classification based on pathognomonic neuroimaging features. J. Neurol. 269, 2440\u20132452. 10.1007/s00415-021-10801-5", "ArticleIdList": ["10.1007/s00415-021-10801-5", "PMC9021106", "34585269"]}, {"Citation": "Beltowski J. (2010). Statins and ALS: the possible role of impaired LXR signaling. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 16, RA73\u2013RA78.", "ArticleIdList": ["20190699"]}, {"Citation": "Bennett S. A., Tanaz R., Cobos S. N., Torrente M. P. (2019). Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease. Transl. Res. 204, 19\u201330. 10.1016/j.trsl.2018.10.002", "ArticleIdList": ["10.1016/j.trsl.2018.10.002", "PMC6331271", "30391475"]}, {"Citation": "Berdy\u0144ski M., Miszta P., Safranow K., Andersen P. M., Morita M., Filipek S., et al. . (2022). SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci. Rep. 12:103. 10.1038/s41598-021-03891-8", "ArticleIdList": ["10.1038/s41598-021-03891-8", "PMC8742055", "34996976"]}, {"Citation": "Borghero G., Sechi M. M., Vasta R., Pierri V., Pili F., Pateri I., et al. . (2023). Spatial clustering of amyotrophic lateral sclerosis in Sardinia, Italy: the contribution of age, sex, and genetic factors. Muscle Nerve 68, 323\u2013328. 10.1002/mus.27939", "ArticleIdList": ["10.1002/mus.27939", "37466098"]}, {"Citation": "B\u00f6sel J., Gandor F., Harms C., Synowitz M., Harms U., Djoufack P. C., et al. . (2005). Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J. Neurochem. 92, 1386\u20131398. 10.1111/j.1471-4159.2004.02980.x", "ArticleIdList": ["10.1111/j.1471-4159.2004.02980.x", "15748157"]}, {"Citation": "Brenner D., Freischmidt A. (2022). Update on genetics of amyotrophic lateral sclerosis. Curr. Opin. Neurol. 35, 672\u2013677. 10.1097/WCO.0000000000001093", "ArticleIdList": ["10.1097/WCO.0000000000001093", "35942673"]}, {"Citation": "Cameron C., Fireman B., Hutton B., Clifford T., Coyle D., Wells G., et al. . (2015). Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst. Rev. 4, 1\u20138. 10.1186/s13643-015-0133-0", "ArticleIdList": ["10.1186/s13643-015-0133-0", "PMC4634799", "26537988"]}, {"Citation": "Chang M. C., Kwak S. G., Park J.-S., Park D. (2021). Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis. Medicine 100:e26751. 10.1097/MD.0000000000026751", "ArticleIdList": ["10.1097/MD.0000000000026751", "PMC8322535", "34397718"]}, {"Citation": "Che\u0142stowska B., Bara\u0144czyk-Kuzma A., Kuzma-Kozakiewicz M. (2021). Dyslipidemia in patients with amyotrophic lateral sclerosis\u2013a case control retrospective study. Amyotroph. Lateral Scler. Front. Degener. 22, 195\u2013205. 10.1080/21678421.2020.1832119", "ArticleIdList": ["10.1080/21678421.2020.1832119", "33103950"]}, {"Citation": "Chen S., Liao Q., Lu K., Zhou J., Huang C., Bi F. (2020). Riluzole exhibits no therapeutic efficacy on a transgenic rat model of amyotrophic lateral sclerosis. Curr. Neurovasc. Res. 17, 275\u2013285. 10.2174/1567202617666200409125227", "ArticleIdList": ["10.2174/1567202617666200409125227", "32271694"]}, {"Citation": "Chen X., Yazdani S., Piehl F., Magnusson P. K. E., Fang F. (2018). Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol. Aging 67, 202.e1. 10.1016/j.neurobiolaging.2018.03.022", "ArticleIdList": ["10.1016/j.neurobiolaging.2018.03.022", "29685649"]}, {"Citation": "Chi\u00f2 A., Logroscino G., Traynor B. J., Collins J., Simeone J. C., Goldstein L. A., et al. . (2013). Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118\u2013130. 10.1159/000351153", "ArticleIdList": ["10.1159/000351153", "PMC4049265", "23860588"]}, {"Citation": "Cho H., Shukla S. (2020). Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis. Pharmaceuticals 14:29. 10.3390/ph14010029", "ArticleIdList": ["10.3390/ph14010029", "PMC7823603", "33396271"]}, {"Citation": "Climent E., Benaiges D., Pedro-Botet J. (2021). Hydrophilic or lipophilic statins? Front. Cardiovasc. Med. 8:687585. 10.3389/fcvm.2021.687585", "ArticleIdList": ["10.3389/fcvm.2021.687585", "PMC8172607", "34095267"]}, {"Citation": "Colman E., Szarfman A., Wyeth J., Mosholder A., Jillapalli D., Levine J., et al. . (2008). An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol. Drug Saf. 17, 1068\u20131076. 10.1002/pds.1643", "ArticleIdList": ["10.1002/pds.1643", "18821724"]}, {"Citation": "D'Amico E., Grosso G., Nieves J. W., Zangh\u00ec A., Factor-Litvak P., Mitsumoto H. (2021). Metabolic abnormalities, dietary risk factors and nutritional management in amyotrophic lateral sclerosis. Nutrients 13:2273. 10.3390/nu13072273", "ArticleIdList": ["10.3390/nu13072273", "PMC8308334", "34209133"]}, {"Citation": "Davis S. A., Itaman S., Khalid-Janney C. M., Sherard J. A., Dowell J. A., Cairns N. J., et al. . (2018). TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 678, 8\u201315. 10.1016/j.neulet.2018.04.053", "ArticleIdList": ["10.1016/j.neulet.2018.04.053", "PMC5975202", "29715546"]}, {"Citation": "Del Tredici K., Braak H. (2022). Neuropathology and neuroanatomy of TDP-43 amyotrophic lateral sclerosis. Curr. Opin. Neurol. 35, 660\u2013671. 10.1097/WCO.0000000000001098", "ArticleIdList": ["10.1097/WCO.0000000000001098", "36069419"]}, {"Citation": "Delpont B., Beauvais K., Jacquin-Piques A., Alavoine V., Rault P., Blanc-Labarre C., et al. . (2019). Clinical features of pain in amyotrophic lateral sclerosis: a clinical challenge. Rev. Neurol. 175, 11\u201315. 10.1016/j.neurol.2017.11.009", "ArticleIdList": ["10.1016/j.neurol.2017.11.009", "30131172"]}, {"Citation": "Deng F., Tuomi S.-K., Neuvonen M., Hirvensalo P., Kulju S., Wenzel C., et al. . (2021). Comparative hepatic and intestinal efflux transport of statins. Drug Metab. Dispos. 49, 750\u2013759. 10.1124/dmd.121.000430", "ArticleIdList": ["10.1124/dmd.121.000430", "34162690"]}, {"Citation": "Diana A., Bongioanni P. (2022). \u201cGlutamate-based treatment for amyotrophic lateral sclerosis/motor neuron disease,\u201d in Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments, ed. Z. M. Pavlovic (Cham: Springer; ), 359\u2013380. 10.1007/978-3-030-87480-3_12", "ArticleIdList": ["10.1007/978-3-030-87480-3_12"]}, {"Citation": "Dodge J. C., Jensen E. H., Yu J., Sardi S. P., Bialas A. R., Taksir T. V., et al. . (2020). Neutral lipid cacostasis contributes to disease pathogenesis in amyotrophic lateral sclerosis. J. Neurosci. 40, 9137\u20139147. 10.1523/JNEUROSCI.1388-20.2020", "ArticleIdList": ["10.1523/JNEUROSCI.1388-20.2020", "PMC7673008", "33051352"]}, {"Citation": "Dreger M., Steinbach R., Otto M., Turner M. R., Grosskreutz J. (2022). Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 93, 422\u2013435. 10.1136/jnnp-2021-327503", "ArticleIdList": ["10.1136/jnnp-2021-327503", "PMC8921583", "35105727"]}, {"Citation": "Drory V. E., Bronipolsky T., Artamonov I., Nefussy B. (2008). Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 273, 81\u201383. 10.1016/j.jns.2008.06.022", "ArticleIdList": ["10.1016/j.jns.2008.06.022", "18678378"]}, {"Citation": "Dupuis L., Corcia P., Fergani A., Gonzalez De Aguilar J.-L., Bonnefont-Rousselot D., Bittar R., et al. . (2008). Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70, 1004\u20131009. 10.1212/01.wnl.0000285080.70324.27", "ArticleIdList": ["10.1212/01.wnl.0000285080.70324.27", "18199832"]}, {"Citation": "Edwards I. R., Star K., Kiuru A. (2007). Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 30, 515\u2013525. 10.2165/00002018-200730060-00005", "ArticleIdList": ["10.2165/00002018-200730060-00005", "17536877"]}, {"Citation": "Elfawy H. A., Das B. (2019). Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: etiologies and therapeutic strategies. Life Sci. 218, 165\u2013184. 10.1016/j.lfs.2018.12.029", "ArticleIdList": ["10.1016/j.lfs.2018.12.029", "30578866"]}, {"Citation": "Fang T., Al Khleifat A., Stahl D. R., Lazo La Torre C., Murphy C., Young C., et al. . (2017). Comparison of the King's and MiToS staging systems for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 227\u2013232. 10.1080/21678421.2016.1265565", "ArticleIdList": ["10.1080/21678421.2016.1265565", "PMC5425622", "28054828"]}, {"Citation": "Farina S., Esposito F., Battistoni M., Biamonti G., Francia S. (2021). Post-translational modifications modulate proteinopathies of TDP-43, FUS and hnRNP-A/B in amyotrophic lateral sclerosis. Front. Mol. Biosci. 8:693325. 10.3389/fmolb.2021.693325", "ArticleIdList": ["10.3389/fmolb.2021.693325", "PMC8287968", "34291086"]}, {"Citation": "Feldman E. L., Goutman S. A., Petri S., Mazzini L., Savelieff M. G., Shaw P. J., et al. . (2022). Amyotrophic lateral sclerosis. Lancet 400, 1363\u20131380. 10.1016/S0140-6736(22)01272-7", "ArticleIdList": ["10.1016/S0140-6736(22)01272-7", "PMC10089700", "36116464"]}, {"Citation": "Ferri G., Ferreira F., Djapic V. (2017). \u201cMulti-domain robotics competitions: the CMRE experience from SAUC-E to the European robotics league emergency robots,\u201d in Ocean 2017-Aberdeen (Aberdeen: IEEE; ), 1\u20137. 10.1109/OCEANSE.2017.8084767", "ArticleIdList": ["10.1109/OCEANSE.2017.8084767"]}, {"Citation": "Filppula A. M., Hirvensalo P., Parviainen H., Ivaska V. E., L\u00f6nnberg K. I., Deng F., et al. . (2021). Comparative hepatic and intestinal metabolism and pharmacodynamics of statins. Drug Metab. Dispos. 49, 658\u2013667. 10.1124/dmd.121.000406", "ArticleIdList": ["10.1124/dmd.121.000406", "34045219"]}, {"Citation": "Fontana I. C., Souza D. G., Souza D. O., Gee A., Zimmer E. R., Bongarzone S. (2023). A medicinal chemistry perspective on excitatory amino acid transporter 2 dysfunction in neurodegenerative diseases. J. Med. Chem. 66, 2330\u20132346. 10.1021/acs.jmedchem.2c01572", "ArticleIdList": ["10.1021/acs.jmedchem.2c01572", "PMC9969404", "36787643"]}, {"Citation": "Fracassi A., Marangoni M., Rosso P., Pallottini V., Fioramonti M., Siteni S., et al. . (2019). Statins and the brain: more than lipid lowering agents? Curr. Neuropharmacol. 17, 59\u201383. 10.2174/1570159X15666170703101816", "ArticleIdList": ["10.2174/1570159X15666170703101816", "PMC6341496", "28676012"]}, {"Citation": "Gagliardi D., Comi G. P., Bresolin N., Corti S. (2019). Micro RNA s as regulators of cell death mechanisms in amyotrophic lateral sclerosis. J. Cell. Mol. Med. 23, 1647\u20131656. 10.1111/jcmm.13976", "ArticleIdList": ["10.1111/jcmm.13976", "PMC6378226", "30614179"]}, {"Citation": "Gagliardi S., Pandini C., Garofalo M., Bordoni M., Pansarasa O., Cereda C. (2018a). Long non coding RNAs and ALS: still much to do. Non-coding RNA Res. 3, 226\u2013231. 10.1016/j.ncrna.2018.11.004", "ArticleIdList": ["10.1016/j.ncrna.2018.11.004", "PMC6260474", "30533570"]}, {"Citation": "Gagliardi S., Zucca S., Pandini C., Diamanti L., Bordoni M., Sproviero D., et al. . (2018b). Long non-coding and coding RNAs characterization in peripheral blood mononuclear cells and spinal cord from amyotrophic lateral sclerosis patients. Sci. Rep. 8:2378. 10.1038/s41598-018-20679-5", "ArticleIdList": ["10.1038/s41598-018-20679-5", "PMC5799454", "29402919"]}, {"Citation": "Gaimari A., Fusaroli M., Raschi E., Baldin E., Vignatelli L., Nonino F., et al. . (2022). Amyotrophic lateral sclerosis as an adverse drug reaction: a disproportionality analysis of the food and drug administration adverse event reporting system. Drug Saf. 45, 663\u2013673. 10.1007/s40264-022-01184-1", "ArticleIdList": ["10.1007/s40264-022-01184-1", "35610460"]}, {"Citation": "Golomb B. A., Kwon E. K., Koperski S., Evans M. A. (2009). Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 32, 649\u2013661. 10.2165/00002018-200932080-00004", "ArticleIdList": ["10.2165/00002018-200932080-00004", "19591530"]}, {"Citation": "Golomb B. A., Verden A., Messner A. K., Koslik H. J., Hoffman K. B. (2018). Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf. 41, 403\u2013413. 10.1007/s40264-017-0620-4", "ArticleIdList": ["10.1007/s40264-017-0620-4", "29427042"]}, {"Citation": "Goutman S. A., Hardiman O., Al-Chalabi A., Chi\u00f3 A., Savelieff M. G., Kiernan M. C., et al. . (2022). Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 21, 480\u2013493. 10.1016/S1474-4422(21)00465-8", "ArticleIdList": ["10.1016/S1474-4422(21)00465-8", "PMC9513753", "35334233"]}, {"Citation": "Gregory J. M., Fagegaltier D., Phatnani H., Harms M. B. (2020). Genetics of amyotrophic lateral sclerosis. Curr. Genet. Med. Rep. 8, 121\u2013131. 10.1007/s40142-020-00194-8", "ArticleIdList": ["10.1007/s40142-020-00194-8"]}, {"Citation": "Group H. P. S. C. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet 360, 7\u201322. 10.1016/S0140-6736(02)09327-3", "ArticleIdList": ["10.1016/S0140-6736(02)09327-3", "12114036"]}, {"Citation": "Group S. C. (2008). SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N. Engl. J. Med. 359, 789\u2013799. 10.1056/NEJMoa0801936", "ArticleIdList": ["10.1056/NEJMoa0801936", "18650507"]}, {"Citation": "Haag M. D. M., Hofman A., Koudstaal P. J., Stricker B. H. C., Breteler M. M. B. (2009). Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 80, 13\u201317. 10.1136/jnnp.2008.150433", "ArticleIdList": ["10.1136/jnnp.2008.150433", "18931004"]}, {"Citation": "Hansson O. (2021). Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963. 10.1038/s41591-021-01382-x", "ArticleIdList": ["10.1038/s41591-021-01382-x", "34083813"]}, {"Citation": "Hartmann H., Ho W. Y., Chang J., Ling S. (2022). Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon? FEBS J. 289, 7688\u20137709. 10.1111/febs.16175", "ArticleIdList": ["10.1111/febs.16175", "34469619"]}, {"Citation": "Hirota T., Fujita Y., Ieiri I. (2020). An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin. Drug Metab. Toxicol. 16, 809\u2013822. 10.1080/17425255.2020.1801634", "ArticleIdList": ["10.1080/17425255.2020.1801634", "32729746"]}, {"Citation": "Hu N., Ji H. (2022). Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol. Sci. 43, 5189\u20135199. 10.1007/s10072-022-06131-7", "ArticleIdList": ["10.1007/s10072-022-06131-7", "35616813"]}, {"Citation": "Iwamoto K., Yoshii Y., Ikeda K. (2009). Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice. Amyotroph. Lateral Scler. 10, 405\u2013409. 10.3109/17482960902870993", "ArticleIdList": ["10.3109/17482960902870993", "19922131"]}, {"Citation": "Jamshidnejad-Tosaramandani T., Kashanian S., Al-Sabri M. H., Kro\u010dianov\u00e1 D., Clemensson L. E., Gentreau M., et al. . (2022). Statins and cognition: modifying factors and possible underlying mechanisms. Front. Aging Neurosci. 14:968039. 10.3389/fnagi.2022.968039", "ArticleIdList": ["10.3389/fnagi.2022.968039", "PMC9421063", "36046494"]}, {"Citation": "Jeong S., Jang W., Shin D. W. (2019). Association of statin use with Parkinson's disease: dose\u2013response relationship. Mov. Disord. 34, 1014\u20131021. 10.1002/mds.27681", "ArticleIdList": ["10.1002/mds.27681", "30938893"]}, {"Citation": "Kabir M. T., Uddin M. S., Abdeen A., Ashraf G. M., Perveen A., Hafeez A., et al. . (2020). Evidence linking protein misfolding to quality control in progressive neurodegenerative diseases. Curr. Top. Med. Chem. 20, 2025\u20132043. 10.2174/1568026620666200618114924", "ArticleIdList": ["10.2174/1568026620666200618114924", "32552649"]}, {"Citation": "Kadhim S. S., Al-Windy S. A., Al-Nami M. S., Al-kuraishy H. M., Al-Gareeb A. I. (2019). Possible role of statins on the inflammatory biomarkers in patients with periodontal disease: a cross-sectional study. Dent. Hypotheses 10, 70\u201375. 10.4103/denthyp.denthyp_60_19", "ArticleIdList": ["10.4103/denthyp.denthyp_60_19"]}, {"Citation": "Kreple C. J., Searles Nielsen S., Schoch K. M., Shen T., Shabsovich M., Song Y., et al. . (2023). Protective effects of lovastatin in a population-based ALS study and mouse model. Ann. Neurol. 93, 881\u2013892. 10.1002/ana.26600", "ArticleIdList": ["10.1002/ana.26600", "36627836"]}, {"Citation": "Lin F.-C., Chuang Y.-S., Hsieh H.-M., Lee T.-C., Chiu K.-F., Liu C.-K., et al. . (2015). Early statin use and the progression of Alzheimer disease: a total population-based case-control study. Medicine 94:e2143. 10.1097/MD.0000000000002143", "ArticleIdList": ["10.1097/MD.0000000000002143", "PMC5059011", "26632742"]}, {"Citation": "Liu G., Sterling N. W., Kong L., Lewis M. M., Mailman R. B., Chen H., et al. . (2017). Statins may facilitate Parkinson's disease: insight gained from a large, national claims database. Mov. Disord. 32, 913\u2013917. 10.1002/mds.27006", "ArticleIdList": ["10.1002/mds.27006", "PMC5466869", "28370314"]}, {"Citation": "Liu X. (2019). Transporter-mediated drug-drug interactions and their significance. Drug Transp. Drug Dispos. Eff. Toxic. 1141, 241\u2013291.", "ArticleIdList": ["31571167"]}, {"Citation": "Mac\u00edas Saint-Gerons D., Castro J. L. (2019). Amyotrophic lateral sclerosis associated with statins. A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase). Eur. J. Clin. Pharmacol. 75, 587\u2013589. 10.1007/s00228-018-2587-1", "ArticleIdList": ["10.1007/s00228-018-2587-1", "30470902"]}, {"Citation": "Mariosa D., Hammar N., Malmstr\u00f6m H., Ingre C., Jungner I., Ye W., et al. . (2017). Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann. Neurol. 81, 718\u2013728. 10.1002/ana.24936", "ArticleIdList": ["10.1002/ana.24936", "28437840"]}, {"Citation": "Mariosa D., Kamel F., Bellocco R., Ronnevi L., Almqvist C., Larsson H., et al. . (2020). Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur. J. Neurol. 27, 1010\u20131016. 10.1111/ene.14190", "ArticleIdList": ["10.1111/ene.14190", "PMC10957794", "32097525"]}, {"Citation": "Masrori P., Van Damme P. (2020). Amyotrophic lateral sclerosis: a clinical review. Eur. J. Neurol. 27, 1918\u20131929. 10.1111/ene.14393", "ArticleIdList": ["10.1111/ene.14393", "PMC7540334", "32526057"]}, {"Citation": "McGuinness B., Craig D., Bullock R., Passmore P. (2009). Statins for the prevention of dementia. Cochrane Database Syst. Rev. 15:CD003160. 10.1002/14651858.CD003160.pub2", "ArticleIdList": ["10.1002/14651858.CD003160.pub2", "19370582"]}, {"Citation": "Mehta P., Raymond J., Punjani R., Larson T., Han M., Bove F., et al. . (2022). Incidence of amyotrophic lateral sclerosis in the United States, 2014\u20132016. Amyotroph. Lateral Scler. Front. Degener. 23, 378\u2013382. 10.1080/21678421.2021.2023190", "ArticleIdList": ["10.1080/21678421.2021.2023190", "35023792"]}, {"Citation": "Mori F., Miki Y., Kon T., Tanji K., Wakabayashi K. (2019). Autophagy is a common degradation pathway for Bunina bodies and TDP-43 inclusions in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 78, 910\u2013921. 10.1093/jnen/nlz072", "ArticleIdList": ["10.1093/jnen/nlz072", "31504678"]}, {"Citation": "Motataianu A., Serban G., Barcutean L., Balasa R. (2022). Oxidative stress in amyotrophic lateral sclerosis: synergy of genetic and environmental factors. Int. J. Mol. Sci. 23:9339. 10.3390/ijms23169339", "ArticleIdList": ["10.3390/ijms23169339", "PMC9409178", "36012603"]}, {"Citation": "Moutinho M., Nunes M. J., Rodrigues E. (2017). The mevalonate pathway in neurons: it's not just about cholesterol. Exp. Cell Res. 360, 55\u201360. 10.1016/j.yexcr.2017.02.034", "ArticleIdList": ["10.1016/j.yexcr.2017.02.034", "28232115"]}, {"Citation": "Murinson B. B., Haughey N. J., Maragakis N. J. (2012). Selected statins produce rapid spinal motor neuron loss in vitro. BMC Musculoskelet. Disord. 13, 1\u20136. 10.1186/1471-2474-13-100", "ArticleIdList": ["10.1186/1471-2474-13-100", "PMC3487793", "22703530"]}, {"Citation": "Nabizadeh F., Balabandian M., Sharafi A. M., Ghaderi A., Rostami M. R., Naser Moghadasi A. (2022). Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Acta Neurol. Belg. 122, 979\u2013986. 10.1007/s13760-021-01753-8", "ArticleIdList": ["10.1007/s13760-021-01753-8", "34322852"]}, {"Citation": "Nakamura R., Kurihara M., Ogawa N., Kitamura A., Yamakawa I., Bamba S., et al. . (2022). Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: roles of sex and hypermetabolism. Sci. Rep. 12:1826. 10.1038/s41598-022-05714-w", "ArticleIdList": ["10.1038/s41598-022-05714-w", "PMC8814149", "35115598"]}, {"Citation": "Nefussy B., Hirsch J., Cudkowicz M. E., Drory V. E. (2011). Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J. Neurol. Sci. 300, 23\u201327. 10.1016/j.jns.2010.10.011", "ArticleIdList": ["10.1016/j.jns.2010.10.011", "21056430"]}, {"Citation": "Prince M., Albanese E., Guerchet M., Prina M. (2014). World Alzheimer Report 2014. Dementia and Risk Reduction: An analysis of protective and modifiable risk factors. Alzheimer's Disease International. Available online at: https://unilim.hal.science/hal-03495430/doc"}, {"Citation": "Re D. B., Le Verche V., Yu C., Amoroso M. W., Politi K. A., Phani S., et al. . (2014). Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 81, 1001\u20131008. 10.1016/j.neuron.2014.01.011", "ArticleIdList": ["10.1016/j.neuron.2014.01.011", "PMC3951532", "24508385"]}, {"Citation": "Renton A. E., Chi\u00f2 A., Traynor B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17\u201323. 10.1038/nn.3584", "ArticleIdList": ["10.1038/nn.3584", "PMC4544832", "24369373"]}, {"Citation": "Rothman K. J., Greenland S., Lash T. L. (2008). Modern epidemiology. Wolters Kluwer Health/Lippincott Williams and Wilkins Philadelphia."}, {"Citation": "Roy A., Pahan K. (2011). Prospects of statins in Parkinson disease. Neuroscientist 17, 244\u2013255. 10.1177/1073858410385006", "ArticleIdList": ["10.1177/1073858410385006", "PMC3132406", "21252380"]}, {"Citation": "Samant N. P., Gupta G. L. (2021). Novel therapeutic strategies for Alzheimer's disease targeting brain cholesterol homeostasis. Eur. J. Neurosci. 53, 673\u2013686. 10.1111/ejn.14949", "ArticleIdList": ["10.1111/ejn.14949", "32852876"]}, {"Citation": "Schultz B. G., Patten D. K., Berlau D. J. (2018). The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl. Neurodegener. 7, 1\u201311. 10.1186/s40035-018-0110-3", "ArticleIdList": ["10.1186/s40035-018-0110-3", "PMC5830056", "29507718"]}, {"Citation": "Schumacher J., Peter R. S., Nagel G., Rothenbacher D., Rosenbohm A., Ludolph A. C., et al. . (2020). Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur. J. Neurol. 27, 1405\u20131414. 10.1111/ene.14300", "ArticleIdList": ["10.1111/ene.14300", "32396653"]}, {"Citation": "Simon T. G., Duberg A.-S., Aleman S., Hagstrom H., Nguyen L. H., Khalili H., et al. . (2019). Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann. Intern. Med. 171, 318\u2013327. 10.7326/M18-2753", "ArticleIdList": ["10.7326/M18-2753", "PMC8246628", "31426090"]}, {"Citation": "Skajaa N., Bakos I., Horv\u00e1th-Puh\u00f3 E., Henderson V. W., Lash T. L., S\u00f8rensen H. T. (2021). Statin initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology 32, 756\u2013762. 10.1097/EDE.0000000000001384", "ArticleIdList": ["10.1097/EDE.0000000000001384", "34183532"]}, {"Citation": "S\u00f8rensen H. T., Lash T. L., Rothman K. J. (2006). Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 44, 1075\u20131082. 10.1002/hep.21404", "ArticleIdList": ["10.1002/hep.21404", "17058242"]}, {"Citation": "Spinelli E. G., Riva N., Rancoita P. M. V., Schito P., Doretti A., Poletti B., et al. . (2020). Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. NeuroImage Clin. 27:102315. 10.1016/j.nicl.2020.102315", "ArticleIdList": ["10.1016/j.nicl.2020.102315", "PMC7327879", "32593977"]}, {"Citation": "Strandberg T. E., Vanhanen H., Tikkanen M. J. (1999). Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 353, 118\u2013119. 10.1016/S0140-6736(05)76154-7", "ArticleIdList": ["10.1016/S0140-6736(05)76154-7", "10023901"]}, {"Citation": "Strong M. J. (2010). The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 288, 1\u201312. 10.1016/j.jns.2009.09.029", "ArticleIdList": ["10.1016/j.jns.2009.09.029", "19840884"]}, {"Citation": "Tang S., Tabet F., Cochran B. J., Cuesta Torres L. F., Wu B. J., Barter P. J., et al. . (2019). Apolipoprotein AI enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. Sci. Rep. 9:1350. 10.1038/s41598-018-38014-3", "ArticleIdList": ["10.1038/s41598-018-38014-3", "PMC6362284", "30718702"]}, {"Citation": "Tedeschi V., Petrozziello T., Secondo A. (2021). Ca2+ dysregulation in the pathogenesis of amyotrophic lateral sclerosis. Int. Rev. Cell Mol. Biol. 363, 21\u201347. 10.1016/bs.ircmb.2021.02.014", "ArticleIdList": ["10.1016/bs.ircmb.2021.02.014", "34392931"]}, {"Citation": "Thompson A. G., Talbot K., Turner M. R. (2022). Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 93, 75\u201381. 10.1136/jnnp-2021-327133", "ArticleIdList": ["10.1136/jnnp-2021-327133", "PMC8685635", "34518331"]}, {"Citation": "Toft S\u00f8rensen H., Lash T. L. (2009). Statins and amyotrophic lateral sclerosis\u2013the level of evidence for an association. J. Intern. Med. 266, 520\u2013526. 10.1111/j.1365-2796.2009.02173.x", "ArticleIdList": ["10.1111/j.1365-2796.2009.02173.x", "19930099"]}, {"Citation": "van Eenennaam R. M., Kruithof W. J., van Es M. A., Kruitwagen-van Reenen E. T., Westeneng H.-J., Visser-Meily J. M. A., et al. . (2020). Discussing personalized prognosis in amyotrophic lateral sclerosis: development of a communication guide. BMC Neurol. 20, 1\u201311. 10.1186/s12883-020-02004-8", "ArticleIdList": ["10.1186/s12883-020-02004-8", "PMC7734773", "33308184"]}, {"Citation": "Verber N. S., Shepheard S. R., Sassani M., McDonough H. E., Moore S. A., Alix J. J. P., et al. . (2019). Biomarkers in motor neuron disease: a state of the art review. Front. Neurol. 10:291. 10.3389/fneur.2019.00291", "ArticleIdList": ["10.3389/fneur.2019.00291", "PMC6456669", "31001186"]}, {"Citation": "Vinceti M., Filippini T., Malagoli C., Violi F., Mandrioli J., Consonni D., et al. . (2019). Amyotrophic lateral sclerosis incidence following exposure to inorganic selenium in drinking water: a long-term follow-up. Environ. Res. 179:108742. 10.1016/j.envres.2019.108742", "ArticleIdList": ["10.1016/j.envres.2019.108742", "31629180"]}, {"Citation": "Vogt M. A., Ehsaei Z., Knuckles P., Higginbottom A., Helmbrecht M. S., Kunath T., et al. . (2018). TDP-43 induces p53-mediated cell death of cortical progenitors and immature neurons. Sci. Rep. 8:8097. 10.1038/s41598-018-26397-2", "ArticleIdList": ["10.1038/s41598-018-26397-2", "PMC5970242", "29802307"]}, {"Citation": "Wagstaff L. R., Mitton M. W., Arvik B. M., Doraiswamy P. M. (2003). Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacother. J. Hum. Pharmacol. Drug Ther. 23, 871\u2013880. 10.1592/phco.23.7.871.32720", "ArticleIdList": ["10.1592/phco.23.7.871.32720", "12885101"]}, {"Citation": "Wahner A. D., Bronstein J. M., Bordelon Y. M., Ritz B. (2008). Statin use and the risk of Parkinson disease. Neurology 70, 1418\u20131422. 10.1212/01.wnl.0000286942.14552.51", "ArticleIdList": ["10.1212/01.wnl.0000286942.14552.51", "PMC3690297", "18184918"]}, {"Citation": "Wang S., Peng D. (2012). Regulation of adipocyte autophagy\u2014The potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I. Lipids Health Dis. 11, 1\u20138. 10.1186/1476-511X-11-131", "ArticleIdList": ["10.1186/1476-511X-11-131", "PMC3478219", "23039759"]}, {"Citation": "Wang W., Wang L., Lu J., Siedlak S. L., Fujioka H., Liang J., et al. . (2016). The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med. 22, 869\u2013878. 10.1038/nm.4130", "ArticleIdList": ["10.1038/nm.4130", "PMC4974139", "27348499"]}, {"Citation": "Wang W., Zhang L., Xia K., Huang T., Fan D. (2023). Mendelian randomization analysis reveals statins potentially increase amyotrophic lateral sclerosis risk independent of peripheral cholesterol-lowering effects. Biomedicines 11:1359. 10.3390/biomedicines11051359", "ArticleIdList": ["10.3390/biomedicines11051359", "PMC10216016", "37239030"]}, {"Citation": "Weisskopf M. G., Levy J., Dickerson A. S., Paganoni S., Leventer-Roberts M. (2022). Statin medications and amyotrophic lateral sclerosis incidence and mortality. Am. J. Epidemiol. 191, 1248\u20131257. 10.1093/aje/kwac054", "ArticleIdList": ["10.1093/aje/kwac054", "PMC9393061", "35333291"]}, {"Citation": "Wolozin B., Wang S. W., Li N.-C., Lee A., Lee T. A., Kazis L. E. (2007). Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5, 1\u201311. 10.1186/1741-7015-5-20", "ArticleIdList": ["10.1186/1741-7015-5-20", "PMC1955446", "17640385"]}, {"Citation": "Wood W. G., Igbavboa U., Muller W. E., Eckert G. P. (2013). Statins, Bcl-2, and apoptosis: cell death or cell protection? Mol. Neurobiol. 48, 308\u2013314. 10.1007/s12035-013-8496-5", "ArticleIdList": ["10.1007/s12035-013-8496-5", "PMC3779518", "23821030"]}, {"Citation": "Wright G. S. A., Antonyuk S. V., Hasnain S. S. (2019). The biophysics of superoxide dismutase-1 and amyotrophic lateral sclerosis. Q. Rev. Biophys. 52:e12. 10.1017/S003358351900012X", "ArticleIdList": ["10.1017/S003358351900012X", "31760962"]}, {"Citation": "Yanae M., Tsubaki M., Satou T., Itoh T., Imano M., Yamazoe Y., et al. . (2011). Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J. Exp. Clin. Cancer Res. 30, 1\u20138. 10.1186/1756-9966-30-74", "ArticleIdList": ["10.1186/1756-9966-30-74", "PMC3163617", "21831290"]}, {"Citation": "Yoshii Y., Hadano S., Otomo A., Kawabe K., Ikeda K., Iwasaki Y. (2010). Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 74, 2027\u20132028. 10.1212/WNL.0b013e3181e03bbe", "ArticleIdList": ["10.1212/WNL.0b013e3181e03bbe", "20548050"]}, {"Citation": "Zeng P., Zhou X. (2019). Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum. Mol. Genet. 28, 688\u2013697. 10.1093/hmg/ddy384", "ArticleIdList": ["10.1093/hmg/ddy384", "PMC6360326", "30445611"]}, {"Citation": "Zheng X., Liao Y., Wang J., Hu S., Rudramurthy G. R., Swamy M. K., et al. . (2018). The antineuroinflammatory effect of simvastatin on lipopolysaccharide activated microglial cells. Evid.-Based Complement. Altern. Med. 2018:9691085. 10.1155/2018/9691085", "ArticleIdList": ["10.1155/2018/9691085", "PMC6247388", "30524484"]}, {"Citation": "Zinman L., Sadeghi R., Gawel M., Patton D., Kiss A. (2008). Are statin medications safe in patients with ALS? Amyotroph. Lateral Scler. 9, 223\u2013228. 10.1080/17482960802031092", "ArticleIdList": ["10.1080/17482960802031092", "18608105"]}]}], "History": [{"Year": "2024", "Month": "4", "Day": "24"}, {"Year": "2024", "Month": "5", "Day": "23"}, {"Year": "2024", "Month": "6", "Day": "21", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "6", "Day": "21", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "6", "Day": "21", "Hour": "4", "Minute": "21"}, {"Year": "2024", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["38903602", "PMC11188367", "10.3389/fnins.2024.1422912"]}}]}